Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: CYBERKEN who wrote (11193)	11/15/1997 7:09:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

CYBERKEN, I agree with you about Biotechs in general and LGND in particular. Last year LGND ran from 11 1/4 to 17, beginning in late November and ending Jan 7, the day of their H&Q presentation. I expect more this year. The amount of news will be markedly greater, and the big boys will participate on the BUY side. I expect LGND's ossilating pattern to end, as more products advance. LGND has been extremely successful in the clinical arena, which is a very strong positive for their stock price because of their pipeline and the underlying technology. The first generation compounds look good, so 2nd and 3rd should be fantastic. Of course the big improvements in health (and LGND's bottom line) will come from combination therapies. Rexinoids and TZDs are a great example, but I expect much more (and obviously LLY is betting on rexinoids and estrogens). LGND is extremely well positioned and investors will reap the rewards. My main concern is Andy, who seems to be getting a bit more positive today.